Stellar Biotechnologies Wins $3M NIH Grant

Port Hueneme-based Stellar Biotechnologies announced last week that the company has been awarded $3M from the Nataional Cancer Institute of the National Institutes of Health for the development and commercialization of anti-cancer vaccines. The company is developing production methods, quality standards, and facilities for commercialing Keyhole Limpet Hemocyanin (KLH) for use in anti-cancer vaccines. KLH-based vaccines are in advanced clinical trials for treating lymphoma, breast, colon and other cancers.